References
- Trauner M, Fickert P, Zollner G, et al. Cellular and molecular mechanisms of cholestasis. In: Blum HE, Maier KP, Sauerbruch T, et al, editors. Liver cirrhosis and its development. Dodrecht (the Netherlands): Kluwer Academic Publishers; 2000. p. 3–20.
- Dirlik M, Canbaz H, Düsmez Apa D, et al. The monitoring of progress in apoptosis of liver cells in bile duct-ligated rats. Turk J Gastroenterol. 2009;20:247–256.
- Lalisang TJ, Sjamsuhidajat R, Siregar NC, et al. Profile of hepatocyte apoptosis and bile lakes before and after bile duct decompression in severe obstructive jaundice patients. Hepatobiliary Pancreat Dis Int. 2010;9:520–523.
- Wang DS, Dou KF, Li KZ, et al. Hepatocellular apoptosis after hepatectomy in obstructive jaundice in rats. World J Gastroenterol. 2003;9:2737–2741.
- Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther. 2009;30:1103–1109.
- Reichen J, Kra¨henbu¨ H, Zimmermann H. Impact of cholestasis on hepatic function: retention of cholephiles and their potential targets. In: Gentilini P, Arias IM, Mclntyre N, et al., editor. Cholestasis. New York: Elsevier Science; 1994. p. 167–175.
- Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 2004;64:1751–1756.
- Luft T, Conzelmann M, Benner A, et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood. 2007;110:4535–4542.
- Yagmur E, Trautwein C, Leers MP, et al. Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clin Biochem. 2007;40:651–655.
- Yilmaz Y, Dolar E, Ulukaya E, et al. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. Med Sci Monit. 2009;39:CR189–CR193.
- Papatheodoridis GV, Hadziyannis E, Tsochatzis E, et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut. 2007;57:500–506.
- Onodera M, Takikawa Y, Kakisaka K, et al. Differential evaluation of hepatocyte apoptosis and necrosis in acute liver injury. Hepatol Res. 2010;40:605–612.
- Michalopoulos GK, Zarnegav R. Hepatocyte growth factor. Hepatology. 1992;15:149–155.
- Makino H, Shimizu H, Ito H, et al. Changes in growth factor and cytokine expression in biliary obstructed rat liver and their relationship with delayed liver regeneration after partial hepatectomy. WJG. 2006; 12:2053–2059.
- Kosai K, Matsumoto K, Funakoshi H, et al. Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology. 1999; 30:151–159.
- Woolbright BL, Antoine DJ, Jenkins RE, et al. Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice. Toxicol Appl Pharmacol. 2013;273:524–531.
- Yamano T, Hirai R, Hato S, et al. Delayed liver regeneration with negative regulation of hepatocyte growth factor and positive regulation of transforming growth factor-beta1 mRNA after portal branch ligation in biliary obstructed rats. Surgery. 2002;131:163–171.
- Lehwald N, Duhme C, Wildner M, et al. HGF and SDF-1-mediated mobilization of CD133+ BMSC for hepatic regeneration following extensive liver resection. Liver Int. 2014;34:89–101.
- Fang Y, Gurusamy KS, Wang Q, et al. Meta-analysis of randomized clinical trials on safety and efficacy of biliary drainage before surgery for obstructive jaundice. Br J Surg. 2013;100:1589–1596.